Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer

Cancer Gene Therapy

Volumn 11, Issue 4, 2004, Pages 263-272

  Zhu, Hong Jïan ^a   Zhang, Zhi Qing ^b   Zeng, Xiang Fu ^c   Wei, Shou Shun ^c   Zhang, Zhi Wen ^d   Guo, Ying Lu ^a  

^a PEKING UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Bladder cancer; Promoter; Uroplakinii

Indexed keywords

DNA FRAGMENT; GENE PRODUCT; GREEN FLUORESCENT PROTEIN; LUCIFERASE; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UROPLAKIN; MESSENGER RNA; UROPLAKIN II;

ADENOVIRUS; ARTICLE; BLADDER CANCER; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INOCULATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPORTER GENE; TARGET ORGAN; TISSUE SPECIFICITY; URINE; UROTHELIUM; ANIMAL; BAGG ALBINO MOUSE; BIOASSAY; BLADDER TUMOR; CANCER TRANSPLANTATION; DISEASE MODEL; DNA FLANKING REGION; DNA RESPONSIVE ELEMENT; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM; METHODOLOGY; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; TUMOR CELL LINE;

5' FLANKING REGION; ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS (GENETICS); RESPONSE ELEMENTS; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 16544374575     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700672     Document Type: Article

References (31)

1. Sandberg AA, Berger CS. Review of chromosome studies in urological tumors. II Cytogenetics and molecular. J Urol. 1994;151:545-560.
2. Hsieh JT, Dinney CPN, Chung LWK. The potential role of gene therapy in the treatment of bladder cancer. Urol Clin North Am. 2000;27:103-109.
3. Elsasser-Beile U, Gutzeit O, Bauer S, Katzenwadel A, Schultze-Seemann W, Wetterauer U. Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas. J Urol. 2000;163:296-299.
4. Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol. 2000;164:526-531.
5. Catalona WJ. Urothelial tumors of the urinary tract. In: Campbell's Urology Vol 2, 6th edn. London: WB Saunders Company; 1992: 1094-1112.
6. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 2000;165:2886-2894.
7. Siemens DR, Austin JC, See WA, Tartaglia J, Ratliff TL. Evaluation of gene transfer efficiency by viral vectors to murine bladder epithelium. J Urol. 2001;165:667-671.
8. Oyama M, Ohigashi T, Hoshi M, et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther. 2000;11:1683-1693.
9. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 1993;53:83-88.
10. Roth JA. Targeting lung cancer genes: a novel approach to cancer prevention and therapy. Semin Thorac Cardiovasc Surg. 1993;5:178-183.
11. Vile RG, Hart IR. In vitro and in vivo targeting gene of gene expression to melanoma cells. Cancer Res. 1993;53:962-967.
12. Peng XY, Won JH, Rutherford T, et al. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res. 2001;61:4405-4413.
13. Brady HJ, Miles CG, Pennington DJ, Dzierzak EA. Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc Natl Acad Sci USA. 1994;91:365-369.
14. Dannull J, Belldegrun AS. Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Br J Urol. 1997;79(Suppl 1):97-103.
15. Wu XR, Lin JH, Walz T, et al. Mammalian uroplakins, a group of highly conserved urothelial differentiation related membrane proteins. J Biol Chem. 1994;269:13716-13724.
16. Yuasa T, Yoshiki T, Isono T, et al. Expression of transitional cell specific genes uroplakin Ia and II in bladder cancer detection of circulating cancer cells in the peripheral blood of metastatic patients. Int J Urol. 1999;6:286-292.
17. Moll R, Wu XR, Lin JH, Sun TT. Uroplakins specific membrane proteins of urothelial umbrella cells as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995;147:1383-1397.
18. Lin JH, Zhao H, Sun TT. A tissue specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. Proc Natl Acad Sci USA. 1995;92:679-683.
19. He TC, Zhou S, Costa LTD, Yu J, Kinzler KW, Vogestein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 1998;95:2509-2514.
20. Roche PJ, Hoare SA, Parker MG. A consensus DNA-binding site for the androgen receptor. Mol Endocrinol. 1992;6:2229-2235.
21. Landis SH, Murray T, Bolden S. Cancer statistics. CA Cancer J Clin. 1999;49:8-31.
22. Bilbao G, Gomez-Navarro J, Curiel DT. Targeted adenoviral vectors for cancer gene therapy. Adv Exp Med Biol. 1998;451:365-374.
23. Venkatesh LK, Arens MQ, Subramanian T, Chinadurai G. Selective induction of toxicity to human cells expressing human immunodeficiency virus type I Tat by a conditionally cytotoxic adenovirus vector. Proc Natl Acad Sci USA. 1990;87:8746-8750.
24. Li SM, Zhang ZT, Chan S, et al. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol. 1999;162:931-935.
25. Sun TT, Zhao H, Provet J, Aebi U, Wu XR. Formation of asymmetric unit membrane during urothelia differentiation. Mol Biol Rep. 1996;23:3-11.
26. Zhang J, Ramesh N, Chen Y, et al. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer Res. 2002;62:3743-3750.
27. Darzynkiewicz Z, Williamson B, Carswell EA, Old LJ. Cell cycle-specific effects of tumor necrosis factor. Cancer Res. 1984;44:83.
28. McIntosh JK, Mule JJ, Travis WD, Rosenberg SA. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice. Cancer Res. 1990;50:2463.
29. Van Moorselaar RJA, Neniers AJMC, Hendriks BTh, et al. In vivo antiproliferative effects of gammainterferon and tumor necrosis factor alpha on a rat renal cell carcinoma model system. J Urol. 1990;143:1247.
30. Shah P, van der Meide PH, Borman T, Schroeder N, Bliss JM, Coombes RC. Effect of human recombinant tumour necrosis factor and rat gamma interferon on nitrosomethylurea induced mammary tumors. Br J Cancer. 1989;59:206.
31. Kleinerman DI, Dinney CP, Zhang WW, Lin SH, Van NT, Hsieh JT. Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model. Cancer Res. 1996;56:3431-3435.